United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - aminophylline hydrate - modified-release tablet - 350mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

napp pharmaceuticals ltd - aminophylline hydrate - modified-release tablet - 225mg

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll).calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

mundipharma pharmaceuticals limited - aminophylline hydrate - prolonged-release tablet - 225 milligram(s) - xanthines; aminophylline

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - tablet - see ingredients - each tablet contains rifapentine 150,0 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

ennogen healthcare (europe) limited - aminophylline hydrate - prolonged-release tablet - xanthines; aminophylline

Ireland - English - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - human alpha1-proteinase inhibitor - powder and solvent for solution for infusion - alfa1 antitrypsin

Ireland - English - HPRA (Health Products Regulatory Authority)

grifols deutschland gmbh - human alpha1-proteinase inhibitor - powder and solvent for solution for infusion - alfa1 antitrypsin

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - levonorgestrel -

United States - English - NLM (National Library of Medicine)

grifols usa, llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - prolastin® -c liquid is an alpha1 -proteinase inhibitor (human) (alpha1 -pi) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1 -pi (alpha1 -antitrypsin deficiency). limitations of use - the effect of augmentation therapy with any alpha1 -pi, including prolastin-c liquid, on pulmonary exacerbations and on the progression of emphysema in alpha1 -pi deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.    - clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with prolastin-c liquid are not available. - prolastin-c liquid is not indicated as therapy for lung disease in patients in whom severe alpha1 -pi deficiency has not been established. prolastin-c liquid is contraindicated in: - iga deficient patients with antibodies against iga, due to the risk of severe hypersensitivity. - patients with a history of anaphylaxis or other sever